VMAT2 gene expression and function as it applies to imaging β-cell mass

Journal of Molecular Medicine

Volumn 86, Issue 1, 2008, Pages 5-16

  Harris, Paul E ^a,b   Ferrara, Caterina ^a   Barba, Pasquale ^a   Polito, Teresa ^b   Freeby, Matthew ^b   Maffei, Antonella ^a,b  

^a INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

cell mass; Diabetes; Gene regulation; Imaging; Vesicular monoamine transporter

Indexed keywords

INSULIN; VESICULAR MONOAMINE TRANSPORTER 2;

AUTOIMMUNE DISEASE; DIABETES MELLITUS; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE MARKER; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; HORMONE SYNTHESIS; HUMAN; HYPERGLYCEMIA; MEASUREMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; REVIEW;

DIABETES MELLITUS; GENE EXPRESSION REGULATION; HUMANS; INSULIN-SECRETING CELLS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 38349073954     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-007-0242-x     Document Type: Review

References (131)

1. Lohr M, Kloppel G (1987) Residual insulin positivity and pancreatic atrophy in relation to duration of chronic type 1 (insulin-dependent) diabetes mellitus and microangiopathy. Diabetologia 30:757-62
2. Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS (2006) Patterns of metabolic progression to type 1 diabetes in the diabetes prevention trial-type 1. Diabetes Care 29:643-649
3. McCulloch DK, Koerker DJ, Kahn SE, Bonner-Weir S, Palmer JP (1991) Correlations of in vivo beta-cell function tests with beta-cell mass and pancreatic insulin content in streptozocin-administered baboons. Diabetes 40:673-679
4. Kjems LL, Kirby BM, Welsh EM, Veldhuis JD, Straume M, McIntyre SS, Yang D, Lefebvre P, Butler PC (2001) Decrease in beta-cell mass leads to impaired pulsatile insulin secretion, reduced postprandial hepatic insulin clearance, and relative hyperglucagonemia in the minipig. Diabetes 50:2001-2012
5. Larsen MO, Gotfredsen CF, Wilken M, Carr RD, Porksen N, Rolin B (2003) Loss of beta-cell mass leads to a reduction of pulse mass with normal periodicity, regularity and entrainment of pulsatile insulin secretion in Gottingen minipigs. Diabetologia 46:195-202
6. Larsen MO, Rolin B(2004) Use of the Gottingen minipig as a model of diabetes, with special focus on type 1 diabetes research. ILAR J 45:303-313
7. Greenbaum CJ (2002) Type 1 diabetes intervention trials: what have we learned? A critical review of selected intervention trials. Clin Immunol 104:97-104
8. Orland MJ, Chyn R, Permutt MA (1985) Modulation of proinsulin messenger RNA after partial pancreatectomy in rats. Relationships to glucose homeostasis. J Clin Invest 75:2047-2055
9. Evgenov NV, Medarova Z, Dai G, Bonner-Weir S, Moore A (2006) In vivo imaging of islet transplantation. Nat Med 12:144-148
10. Kim SJ, Doudet DJ, Studenov AR, Nian C, Ruth TJ, Gambhir SS, McIntosh CH (2006) Quantitative micro positron emission tomography (PET) imaging for the in vivo determination of pancreatic islet graft survival. Nat Med 12:1423-1428
11. Souza F, Freeby M, Hultman K, Simpson N, Herron A, Witkowsky P, Liu E, Maffei A, Harris PE (2006) Current progress in non-invasive imaging of beta cell mass of the endocrine pancreas. Curr Med Chem 13:2761-2773
12. Simpson NR, Souza F, Witkowski P, Maffei A, Raffo A, Herron A, Kilbourn M, Jurewicz A, Herold K, Liu E, Hardy MA, Van Heertum R, Harris PE (2006) Visualizing pancreatic beta-cell mass with [11C]DTBZ. Nucl Med Biol 33:855-864
13. Souza F, Simpson N, Raffo A, Saxena C, Maffei A, Hardy M, Kilbourn M, Goland R, Leibel R, Mann JJ, Van Heertum R, Harris PE (2006) Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model. J Clin Invest 116:1506-1513
14. Frey KA, Koeppe RA, Kilbourn MR (2001) Imaging the vesicular monoamine transporter. Adv Neurol 86:237-247
15. Anlauf M, Eissele R, Schafer MK, Eiden LE, Arnold R, Pauser U, Kloppel G, Weihe E (2003) Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors. J Histochem Cytochem 51:1027-1040
16. Weihe E, Schafer MK, Erickson JD, Eiden LE (1994) Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat. J Mol Neurosci 5:149-164
17. Maffei A, Liu Z, Witkowski P, Moschella F, Del Pozzo G, Liu E, Herold K, Winchester RJ, Hardy MA, Harris PE (2004) Identification of tissue-restricted transcripts in human islets. Endocrinology 145:4513-4521
18. Weihe E, Eiden LE (2000) Chemical neuroanatomy of the vesicular amine transporters. FASEB J 14:2435-2449
19. Anlauf M, Schafer MKH, Schwark T, von Wurmb-Schwark N, Brand V, Sipos B, Horny H-P, Parwaresch R, Hartschuh W, Eiden LE, Kloppel G, Weihe E (2006) Vesicular Monoamine Transporter 2 (VMAT2) Expression in Hematopoietic Cells and in Patients with Systemic Mastocytosis. J Histochem Cytochem 54:201-213
20. Eiden LE (2000) The vesicular neurotransmitter transporters: current perspectives and future prospects. FASEB J 14:2396-2400
21. Erickson JD, Schafer MKH, Bonner TI, Eiden LE, Weihe E (1996) Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci USA 93:5166-5171
22. Fon EA, Pothos EN, Sun BC, Killeen N, Sulzer D, Edwards RH (1997) Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 19:1271-1283
23. Peter D, Liu Y, Sternini C, de Giorgio R, Brecha N, Edwards RH (1995) Differential expression of two vesicular monoamine transporters. J Neurosci 15:6179-6188
24. Mezey E, Eisenhofer G, Harta G, Hansson S, Gould L, Hunyady B, Hoffman BJ (1996) A novel nonneuronal catecholaminergic system: exocrine pancreas synthesizes and releases dopamine. Proc Natl Acad Sci USA 93:10377-10382
25. Anlauf M, Schafer MKH, Depboylu C, Hartschuh W, Eiden LE, Kloppel G, Weihe E (2004) The Vesicular Monoamine Transporter 2 (VMAT2) is expressed by normal and tumor cutaneous mast cells and langerhans cells of the skin but is absent from langerhans cell histiocytosis. J Histochem Cytochem 52:779-788
26. Uccella S, Cerutti R, Vigetti D, Furlan D, Oldrini R, Carnevali I, Pelosi G, La Rosa S, Passi A, Capella C (2006) Histidine decarboxylase, DOPA decarboxylase, and vesicular monoamine transporter 2 expression in neuroendocrine tumors: immunohistochemical study and gene expression analysis. J Histochem Cytochem 54:863-875
27. Rindi G, Paolotti D, Fiocca R, Wiedenmann B, Henry JP, Solcia E (2000) Vesicular monoamine transporter 2 as a marker of gastric enterochromaffin-like cell tumors. Virchows Arch 436:217-223
28. Tanimoto A, Matsuki Y, Tomita T, Sasaguri T, Shimajiri S, Sasaguri Y (2004) Histidine decarboxylase expression in pancreatic endocrine cells and related tumors. Pathol Int 54:408-412
29. Graff L, Frungieri M, Zanner R, Pohlinger A, Prinz C, Gratzl M (2002) Expression of histidine decarboxylase and synthesis of histamine by human small cell lung carcinoma. Am J Pathol 160:1561-1565
30. Brunk I, Blex C, Rachakonda S, Holtje M, Winter S, Pahner I, Walther DJ, Ahnert-Hilger G (2006) The first luminal domain of vesicular monoamine transporters mediates G-protein-dependent regulation of transmitter uptake. J Biol Chem 281:33373-33385
31. Brunk I, Holtje M, von Jagow B, Winter S, Sternberg J, Blex C, Pahner I, Ahnert-Hilger G (2006) Regulation of vesicular monoamine and glutamate transporters by vesicle-associated trimeric G proteins: new jobs for long-known signal transduction molecules. Handb Exp Pharmacol 175:305-325
32. Ahnert-Hilger G, Höltje M, Pahner I, Winter S, Brunk I (2003) Regulation of vesicular neurotransmitter transporters. Rev Physiol Biochem Pharmacol 150:140-160
33. Pothos EN, Larsen KE, Krantz DE, Liu Y-j, Haycock JW, Setlik W, Gershon MD, Edwards RH, Sulzer D (2000) Synaptic vesicle transporter expression regulates vesicle phenotype and quantal size. J Neurosci 20:7297-7306
34. Song H, Ming G, Fon E, Bellocchio E, Edwards RH, Poo M (1997) Expression of a putative vesicular acetylcholine transporter facilitates quantal transmitter packaging. Neuron 18:815-826
35. Travis ER,Wang Y-M, Michael DJ, Caron MG, Wightman RM (2000) Differential quantal release of histamine and 5-hydroxytryptamine from mast cells of vesicular monoamine transporter 2 knockout mice. Proc Natl Acad Sci USA 97:162-167
36. Wang YM, Gainetdinov RR, Fumagalli F, Xu F, Jones SR, Bock CB, Miller GW, Wightman RM, Caron MG (1997) Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 19:1285-1296
37. Wojcik SM, Rhee JS, Herzog E, Sigler A, Jahn R, Takamori S, Brose N, Rosenmund C (2004) An essential role for vesicular glutamate transporter 1 (VGLUT1) in postnatal development and control of quantal size. Proc Natl Acad Sci USA 101:7158-7163
38. Moechars D, Weston MC, Leo S, Callaerts-Vegh Z, Goris I, Daneels G, Buist A, Cik M, van der Spek P, Kass S, Meert T, D'Hooge R, Rosenmund C, Hampson RM (2006) Vesicular Glutamate Transporter VGLUT2 expression levels control quantal size and neuropathic pain. J Neurosci 26:12055-12066
39. Takahashi N, Miner LL, Sora I, Ujike H, Revay RS, Kostic V, Jackson-Lewis V, Przedborski S, Uhl GR (1997) VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci USA 94:9938-9943
40. Fumagalli F, Gainetdinov RR, Wang Y-M, Valenzano KJ, Miller GW, Caron MG (1999) Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J Neurosci 19:2424-2431
41. Johnson-Davis KL, Truong JG, Fleckenstein AE, Wilkins DG (2004) Alterations in vesicular dopamine uptake contribute to tolerance to the neurotoxic effects of methamphetamine. J Pharmacol Exp Ther 309:578-586
42. Glatt CE, DeYoung JA, Delgado S, Service SK, Giacomini KM, Edwards RH Risch N, Freimer NB (2001) Screening a large reference sample to identify very low frequency sequence variants: comparisons between two genes. Nat Genet 27:435-438
43. Burman J, Tran CH, Glatt C, Freimer NB, Edwards RH (2004) The effect of rare human sequence variants on the function of vesicular monoamine transporter 2. Pharmacogenetics 14:587-594
44. Glatt CE, Wahner AD, White DJ, Ruiz-Linares A, Ritz B (2006) Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. Hum Mol Genet 15:299-305
45. Lin Z, Walther D, Yu X-Y, Li S, Drgon T, Uhl GR (2005) SLC18A2 promoter haplotypes and identification of a novel protective factor against alcoholism. Hum Mol Genet 14:1393-1404
46. Albin RL, Koeppe RA, Bohnen NI, Nichols TE, Meyer P, Wernette K, Minoshima S, Kilbourn MR, Frey KA(2003) Increased ventral striatal monoaminergic innervation in Tourette syndrome. Neurology 61:310-315
47. Frey KA, Koeppe RA, Kilbourn MR,Vander Borght TM, Albin RL, Gilman S, Kuhl DE (1996) Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol 40:873-884
48. Zubieta JK, Huguelet P, Ohl LE, Koeppe RA, Kilbourn MR, Carr JM, Giordani BJ, Frey KA (2000) High vesicular monoamine transporter binding in asymptomatic bipolar I disorder: sex differences and cognitive correlates. Am J Psychiatry 157:1619-1628
49. Guardiola J, Maffei A, Lauster R, Mitchison NA, Accolla RS, Sartoris S (1996) Functional significance of polymorphism among MHC class II gene promoters. Tissue Antigens 48:615-625
50. Maffei A, Harris PE, Reed EF, Del Pozzo G, Ciullo M, Suciu-Foca N, Guardiola J (1997) Differential expression of insulin-dependent diabetes mellitus-associated HLA-DQA1 alleles in vivo. Eur J Immunol 27:1549-1556
51. Hall FS, Sora I, Uhl GR (2003) Sex-dependent modulation of ethanol consumption in vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) knockout mice. Neuropsychopharmacology 28:620-628
52. Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, Wudel J, Pal PK, de la Fuente-Fernandez R, Calne DB, Stoessl AJ (2000) In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 47:493-503
53. Miller GW, Erickson JD, Perez JT, Penland SN, Mash DC, Rye DB, Levey AI (1999) Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp Neurol 156:138-148
54. Miller GW, Erickson JD, Perez JT, Penland SN, Mash DC, Rye DB, Levey AI (1999) Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp Neurol 156:138-148
55. Lu W, Wolf ME (1997) Expression of dopamine transporter and vesicular monoamine transporter 2 mRNAs in rat midbrain after repeated amphetamine administration. Brain Res Mol Brain Res 49:137-148
56. Richardson JR, Miller GW (2004) Acute exposure to aroclor 1016 or 1260 differentially affects dopamine transporter and vesicular monoamine transporter 2 levels. Toxicol Lett 148:29-40
57. Rusnak M, Kvetnansky R, Jelokova J, Palkovits M (2001) Effect of novel stressors on gene expression of tyrosine hydroxylase and monoamine transporters in brainstem noradrenergic neurons of long-term repeatedly immobilized rats. Brain Res 899:20-35
58. Jankovic J, Chen S, Le WD (2005) The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. Prog Neurobiol 77:128
59. Smits SM, Ponnio T, Conneely OM, Burbach JPH, Smidt MP (2003) Involvement of Nurr1 in specifying the neurotransmitter identity of ventral midbrain dopaminergic neurons. Eur J Neurosci 18:1731-1738
60. Watson F, Deavall DG, Macro JA, Kiernan R, Dimaline R (1999) Transcriptional activation of vesicular monoamine transporter 2 in the pre-B cell line Ea3.123. Biochem J 337(Pt 2):193-199
61. Watson F, Kiernan RS, Deavall DG, Varro A, Dimaline R (2001) Transcriptional activation of the rat vesicular monoamine transporter 2 promoter in gastric epithelial cells. Regulation by gastrin. J Biol Chem 276:7661-7671
62. Desnos C, Laran M-P, Langley K, Aunis D, Henry J-P (1995) Long term stimulation changes the vesicular monoamine transporter content of chromaffin granules. J Biol Chem 270:16030-16038
63. Prinz C, Zanner R, Gerhard M, Mahr S, Neumayer N, Hohne-Zell B, Gratzl, M (1999) The mechanism of histamine secretion from gastric enterochromaffin-like cells. Am J Physiol Cell Physiol 277:C845-C855
64. Iacangelo AL, Eiden LE (1995) Chromogranin A: current status as a precursor for bioactive peptides and a granulogenic/sorting factor in the regulated secretory pathway. Regulatory Pept 58:65-88
65. O'Connor DT, Wu H, Gill BM, Rozansky DJ, Tang K, Mahata SK, Mahata M, Eskeland NL, Videen JS, Zhang X et al (1994) Hormone storage vesicle proteins. Transcriptional basis of the widespread neuroendocrine expression of chromogranin A, and evidence of its diverse biological actions, intracellular and extracellular. Ann NY Acad Sci 733:36-45
66. Dimaline R, Evans D, Forster ER, Sandvik AK, Dockray GJ (1993) Control of gastric corpus chromogranin A messenger RNA abundance in the rat. Am J Physiol Gastrointest Liver Physiol 264:G583-G588
67. Dimaline R, Sandvik AK, Evans D, Forster ER, Dockray GJ (1993) Food stimulation of histidine decarboxylase messenger RNA abundance in rat gastric fundus. J Physiol (Lond) 465:449-458
68. Lambrecht NW, Yakubov I, Sachs G (2007) Fasting induced changes in ECL cell gene expression. Physiol Genomics 0:00252.2006v1
69. Kazumori H, Ishihara S, Rumi MAK, Ortega-Cava CF, Kadowaki Y, Kinoshita Y (2004) Transforming growth factor-{alpha} directly augments histidine decarboxylase and vesicular monoamine transporter 2 production in rat enterochromaffin-like cells. Am J Physiol Gastrointest Liver Physiol 286:G508-G514
70. Rehavi M, Goldin M, Roz N, Weizman A (1998) Regulation of rat brain vesicular monoamine transporter by chronic treatment with ovarian hormones. Mol Brain Res 57:31-37
71. Jakobsen AM, Andersson P, Saglik G, Andersson E, Kolby L, Erickson JD, Forssell-Aronsson E, Wangberg B, Ahlman H, Nilsson O (2001) Differential expression of vesicular monoamine transporter (VMAT) 1 and 2 in gastrointestinal endocrine tumours. J Pathol 195:463-472
72. Atouf F, Czernichow P, Scharfmann R (1997) Expression of neuronal traits in pancreatic beta cells. Implication of neuron-restrictive silencing factor/repressor element silencing transcription factor, a neuron-restrictive silencer. J Biol Chem 272:1929-1934
73. Bird JL, Wright EE, Feldman JM (1980) Pancreatic islets: a tissue rich in serotonin. Diabetes 29:304-308
74. Cegrell L (1968) The occurrence of biogenic monoamines in the mammalian endocrine pancreas. Acta Physiol Scand Suppl 314:1-60
75. Cetin Y (1992) Biogenic amines in the guinea pig endocrine pancreas. Life Sci 50:1343-1350
76. Ekholm R, Ericson LE, Lundquist I (1971) Monoamines in the pancreatic islets of the mouse. Subcellular localization of 5-hydroxytryptamine by electron microscopic autoradiography. Diabetologia 7:339-348
77. Hansen SE, Hedeskov CJ(1977) Simultaneous determination of the content of serotonin, dopamine, noradrenaline and adrenaline in pancreatic islets isolated from fed and starved mice. Acta Endocrinol (Copenh) 86:820-832
78. Jaim-Etcheverry G, Zieher LM (1968) Electron microscopic cytochemistry of 5-hydroxytryptamine (5-HT) in the beta cells of guinea pig endocrine pancreas. Endocrinology 83:917-923
79. Lundquist I, Ahren B, Hansson C, Hakanson R (1989) Monoamines in pancreatic islets of guinea pig, hamster, rat, and mouse determined by high performance liquid chromatography. Pancreas 4:662-667
80. Mahony C, Feldman JM (1977) Species variation in pancreatic islet monoamine uptake and action. Diabetes 26:257-261
81. Wilson JP, Downs RW Jr, Feldman JM, Lebovitz HE (1974) Beta cell monoamines: further evidence for their role in modulating insulin secretion. Am J Physiol 227:305-312
82. Zern RT, Bird JL, Feldman JM (1980) Effect of increased pancreatic islet norepinephrine, dopamine and serotonin concentration on insulin secretion in the golden hamster. Diabetologia 18:341-346
83. Henquin JC (2000) Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49:1751-1760
84. Ahren B, Wierup N, Sundler F (2006) Neuropeptides and the regulation of islet function. Diabetes 55(Suppl 2):S98-S107
85. Brunicardi FC, Shavelle DM, Andersen DK (1995) Neural regulation of the endocrine pancreas. Int J Pancreatol 18:177-195
86. Gilon P, Henquin JC (2001) Mechanisms and physiological significance of the cholinergic control of pancreatic beta-cell function. Endocr Rev 22:565-604
87. Sharp GW (1996) Mechanisms of inhibition of insulin release. Am J Physiol 271:C1781-C1799
88. 2+-induced insulin secretion from electrically permeabilised islets of Langerhans. FEBS Lett 219:139-144
89. Lindstrom P, Sehlin J (1983) Mechanisms underlying the effects of 5-hydroxytryptamine and 5-hydroxytryptophan in pancreatic islets. A proposed role for L-aromatic amino acid decarboxylase. Endocrinology 112:1524-1529
90. Persaud SJ, Jones PM, Howell SL (1993) Activation of protein kinase C partially alleviates noradrenaline inhibition of insulin secretion. Biochem J 289(Pt 2):497-501
91. Sener A, Blachier F, Rasschaert J, Malaisse WJ (1990) Stimulus-secretion coupling of arginine-induced insulin release: comparison with histidine-induced insulin release. Endocrinology 127:107-113
92. 2+-independent insulin release independently from its action on adenylyl cyclase. Endocr J 48:647-654
93. Borelli MI, Villar MJ, Orezzoli A, Gagliardino JJ (1997) Presence of DOPA decarboxylase and its localisation in adult rat pancreatic islet cells. Diabetes Metab 23:161-163
94. Borelli MI, Gagliardino JJ (2001) Possible modulatory effect of endogenous islet catecholamines on insulin secretion. BMC Endocr Disord 1:1
95. Borelli MI, Rubio M, Garcia ME, Flores LE, Gagliardino JJ (2003) Tyrosine hydroxylase activity in the endocrine pancreas: changes induced by short-term dietary manipulation. BMC Endocr Disord 3:2
96. Iturriza FC, Thibault J (1993) Immunohistochemical investigation of tyrosine-hydroxylase in the islets of Langerhans of adult mice, rats and guinea pigs. Neuroendocrinology 57:476-480
97. Kitamura N, Mori Y, Hondo E, Baltazar ET, Yamada J (1999) An immunohistochemical survey of catecholamine-synthesizing enzyme-immunoreactive nerves and endocrine cells in the bovine pancreas. Anat Histol Embryol 28:81-84
98. Watanabe T, Nagatsu I (1991) Immunohistochemical colocalization of insulin, aromatic L-amino acid decarboxylase and dopamine beta-hydroxylase in islet B cells of chicken pancreas. Cell Tissue Res 263:131-136
99. Feldman JM, Chapman B (1975) Characterization of pancreatic islet monoamine oxidase. Metabolism 24:581-588
100. Lenzen S, Freisinger-Treichel M, Panten U (1987) Monoamine oxidase in rat and bovine endocrine tissues. J Neurochem 49:1183-1190
101. Lenzen S, Nahrstedt H, Panten U (1983) Monoamine oxidase in pancreatic islets, exocrine pancreas, and liver from rats. Characterization with clorgyline, deprenyl, pargyline, tranylcypromine, and amezinium. Naunyn Schmiedebergs Arch Pharmacol 324:190-195
102. Pizzinat N, Chan SL, Remaury A, Morgan NG, Parini A (1999) Characterization of monoamine oxidase isoforms in human islets of Langerhans. Life Sci 65:441-448
103. Saura J, Kettler R, Da Prada M, Richards JG (1992) Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J Neurosci 12:1977-1999
104. Stenstrom A, Panagiotidis G, Lundquist I (1989) Monoamine oxidase (MAO) in pancreatic islets of the mouse: some characteristics and the effect of chemical sympathectomy. Diabetes Res 11:81-84
105. Huang YH, Ito A, Arai R (2005) Immunohistochemical localization of monoamine oxidase type B in pancreatic islets of the rat. J Histochem Cytochem 53:1149-1158
106. Aleyassine H, Gardiner RJ (1975) Dual action of antidepressant drugs (MAO inhibitors) on insulin release. Endocrinology 96:702-710
107. Ahren B (2000) Autonomic regulation of islet hormone secretion- implications for health and disease. Diabetologia 43:393-410
108. Rubi B, Ljubicic S, Pournourmohammadi S, Carobbio S, Armanet M, Bartley C, Maechler P (2005) Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. J Biol Chem 280:36824-36832
109. Shankar E, Santhosh KT, Paulose CS (2006) Dopaminergic regulation of glucose-induced insulin secretion through dopamine D2 receptors in the pancreatic islets in vitro. IUBMB Life 58:157-163
110. Ahren B, Taborsky GJ Jr, Porte D Jr (1986) Neuropeptidergic versus cholinergic and adrenergic regulation of islet hormone secretion. Diabetologia 29:827-836
111. El-Mansoury AM, Morgan NG (1998) Activation of protein kinase C modulates alpha2-adrenergic signalling in rat pancreatic islets. Cell Signal 10:637-643
112. Lundquist I (1971) Insulin secretion. Its regulation by monoamines and acid amyloglucosidase. Acta Physiol Scand Suppl 372:1-47
113. Ericson LE, Hakanson R, Lundquist I (1977) Accumulation of dopamine in mouse pancreatic B-cells following injection of l-DOPA. Localization to secretory granules and inhibition of insulin secretion. Diabetologia 13:117-1124
114. Arneric SP, Chow SA, Long JP, Fischer LJ (1984) Inhibition of insulin release from rat pancreatic islets by drugs that are analogues of dopamine. Diabetes 33:888-893
115. Barker CJ, Leibiger IB, Leibiger B, Berggren P-O (2002) Phosphorylated inositol compounds in beta -cell stimulus-response coupling. Am J Physiol Endocrinol Metab 283:E1113-E1122
116. Duttaroy A, Zimliki CL, Gautam D, Cui Y, Mears D, Wess J (2004) Muscarinic stimulation of pancreatic insulin and glucagon release is abolished in M3 muscarinic acetylcholine receptor-deficient mice. Diabetes 53:1714-1720
117. Johnson DE, Yamazaki H, Ward KM, Schmidt AW, Lebel WS, Treadway JL, Gibbs EM, Zawalich WS, Rollema H (2005) Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes 54:1552-1558
118. Llorente MD, Urrutia V (2006) Diabetes, psychiatric disorders, and the metabolic effects of antipsychotic medications. Clin Diabetes 24:18-24
119. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R (2002) Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 159:561-566
120. Hayashi M, Otsuka M, Morimoto R, Muroyama A, Uehara S, Yamamoto A, Moriyama Y (2003) Vesicular inhibitory amino acid transporter is present in glucagon-containing secretory granules in alphaTC6 cells, mouse clonal alpha-cells, and alpha-cells of islets of Langerhans. Diabetes 52:2066-2074
121. Hoy M, Maechler P, Efanov AM, Wollheim CB, Berggren PO, Gromada J (2002) Increase in cellular glutamate levels stimulates exocytosis in pancreatic beta-cells. FEBS Lett 531:199-203
122. 2+-dependent exocytosis of L-glutamate by alphaTC6, clonal mouse pancreatic alpha-cells. Diabetes 50:1012-1020
123. Brice NL,Varadi A, Ashcroft SJ, Molnar E (2002) Metabotropic glutamate and GABA(B) receptors contribute to the modulation of glucose-stimulated insulin secretion in pancreatic beta cells. Diabetologia 45:242-252
124. Storto M, Capobianco L, Battaglia G, Molinaro G, Gradini R, Riozzi B, Di Mambro A, Mitchell KJ, Bruno V, Vairetti MP, Rutter GA, Nicoletti F (2006) Insulin secretion is controlled by mGlu5 metabotropic glutamate receptors. Mol Pharmacol 69:1234-1241
125. Uehara S, Muroyama A, Echigo N, Morimoto R, Otsuka M, Yatsushiro S, Moriyama Y (2004) Metabotropic glutamate receptor type 4 is involved in autoinhibitory cascade for glucagon secretion by alpha-cells of islet of Langerhans. Diabetes 53:998-1006
126. Chapman AG, Nanan K, Williams M, Meldrum BS (2000) Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styryl-pyridine (SIB 1893). Neuropharmacology 39:1567-1574
127. Alexander GM, Godwin DW (2006) Metabotropic glutamate receptors as a strategic target for the treatment of epilepsy. Epilepsy Res 71:1-22
128. Bai L, Zhang X, Ghishan FK (2003) Characterization of vesicular glutamate transporter in pancreatic alpha- and beta-cells and its regulation by glucose. Am J Physiol Gastrointest Liver Physiol 284:G808-G814
129. Maffei A, Harris PE (2007) Targeting vesicular monoamine transporter Type 2 for noninvasive PET-based β-cell mass measurements. Expert Rev Endocrinol Metab 2:35-46
130. Szkudelski T (2001) The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 50:537-546
131. Polychronakos C (2004) Animal models of spontaneous autoimmune diabetes: notes on their relevance to the human disease. Curr Diab Rep 4:151-154